ProImmune Limited Launches Novel Class-Leading CFSE T Cell Proliferation Assays for Assessing Drug Immunogenicity Risk  
12/14/2009 8:30:51 AM

OXFORD, England--(BUSINESS WIRE)--ProImmune Ltd, a leader in epitope discovery, immunogenicity and immune monitoring products and services, has launched CFSE T cell proliferation assays for immunogenicity risk assessment. The new highly sensitive assays form part of ProImmune’s REVEAL Immunogenicity System, a suite of tools used in the design and selection of biological drug leads at the preclinical stage.